Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Sirius XM Holdings Inc (SIRI) Price & Performance

Bristol-Myers Squibb CoTrade
Sirius XM Holdings IncTrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Sirius XM Holdings Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while Sirius XM Holdings Inc trades at $28.55 (market cap $9.70B). The key difference: Bristol-Myers Squibb Co is far larger — about 13.4× Sirius XM Holdings Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.

BMYSIRI
Market Cap
$129.94B$9.70B
Sector
HealthMedia
52-Week High
$65.89$32.59
52-Week Low
$42.60$19.92
Enterprise Value
$163.92B$18.98B
Dividend Yield
3.96%3.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

Sirius XM Holdings Inc

Sirius XM Holdings (SIRI) trades at $28.40, down 1.32% with bearish technical signals despite attractive valuation metrics including P/E of 11.56 and P/B of 0.81. The company reported mixed Q2 2026 results with a revenue beat but earnings miss, while maintaining stable cash flow and announcing a $0.27 dividend. Recent news highlights satellite communications growth potential and institutional positioning.

SIRI presents a value opportunity with strong cash generation and dividend yield, though near-term headwinds include subscriber challenges and debt levels. Analyst consensus remains bullish with $33.17 price target representing 17% upside, but investors should monitor execution on subscriber retention and competitive pressures in the evolving audio streaming landscape.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Sirius XM Holdings Inc

SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.

Read more on SIRI